Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Neoantigen Targeted Therapies Market Grown from 2024 to 2025?

In the last few years, the market for neoantigen targeted therapies has experienced a significant expansion. The market is projected to increase from $3.4 billion in 2024 to $4.72 billion in 2025, with a compound annual growth rate (CAGR) of 38.7%. Factors contributing to the growth during the historic period include advancements in genomic sequencing, evolution of immunotherapy, enhanced understanding of tumor immunology, the clinical success of checkpoint inhibitors, and progress in molecular profiling.

What Growth Rate Is Anticipated for the Neoantigen Targeted Therapies Market in the Coming Years?

The market for neoantigen targeted therapies is anticipated to witness an exponential expansion over the next few years. The market value is projected to reach $16.01 billion in 2029, growing at a compound annual growth rate (CAGR) of 35.7%. This anticipated growth during the forecast period can be linked to the advancement in bioinformatics, the growth of precision medicine, the development of neoantigen vaccines, the strategic combination of therapeutics, and biomarker validation. Key trends for the forecast period include the management of neoantigen resistance, neoantigen-primed adoptive cell therapies, combined neoantigen-based therapies, the incorporation of real-world data, and improved predictive models.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

Who Are the Leading Companies in the Neoantigen Targeted Therapies Market?

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

What Are the Key Drivers of the Neoantigen Targeted Therapies Market?

The neoantigen targeted therapies market’s growth is anticipated to be fueled by the increasing number of cancer occurrences. The term cancer incidence relates to the total number of new cancer diagnoses within a specific demographic over a set time frame. Neoantigen-targeted treatments are typically combined to combat various cancer types. For example, according to the American Cancer Society, a voluntary health organization based in the US, there were about 1.9 million new cancer diagnoses in the US in 2022, showing a substantial rise from prior years. In addition, approximately 609,360 deaths were linked to cancer in the US in 2022, highlighting the profound seriousness and the overwhelming effect this disease has on sufferers and their loved ones. Hence, the upsurge in cancer incidence is a critical driving factor for the expanded growth of the neoantigen targeted therapies market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

What Are the Key Market Segments in the Neoantigen Targeted Therapies Industry?

The neoantigen targeted therapies market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

What Are the Latest Trends in the Neoantigen Targeted Therapies Market?

In order to overcome the hurdles of current immunotherapy in treating solid tumors, leading organizations in the neoantigen targeted therapies sector are adopting a collaborative strategy to individualize cancer treatments. This approach enables companies to tap into each other’s unique strengths and resources for shared benefits and triumphs. Take for example the collaboration in January 2023 between BioNTech SE, a biotech firm based in Germany, and the UK Government. Their joint effort seeks to provide personalized mRNA cancer immunotherapies for around 10,000 patients by 2030. It encompasses several key domains like the advancement of cancer immunotherapies, infectious disease vaccine research, and the establishment of a research and development centre in Cambridge. Using the UK’s clinical trial infrastructure and health data resources, they aim to enhance patient recruitment and select the proper trial locations for BioNTech’s mRNA therapies. The company intends to kickstart its initial clinical trials in the UK within the year, with a focus on cancer vaccines that could potentially be incorporated into standard treatment procedures given their effectiveness.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

What Are the Key Regional Markets in the Neoantigen Targeted Therapies Industry?

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11944

This Report Delivers Insight On:

1. How big is the neoantigen targeted therapies market, and how is it changing globally?

2. Who are the major companies in the neoantigen targeted therapies market, and how are they performing?

3. What are the key opportunities and risks in the neoantigen targeted therapies market right now?

4. Which products or customer segments are growing the most in the neoantigen targeted therapies market?

5. What factors are helping or slowing down the growth of the neoantigen targeted therapies market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model